

M

CHFP025

Please do not
write in
this margin

Please complete
legibly, preferably
in black type, or
bold block lettering

*insert full name
of Company

COMPANIES FORM No. 395

215 427/78

Particulars of a mortgage or charge

395


A fee of £13 is payable to Companies House in respect
of each register entry for a mortgage or charge.

Pursuant to section 395 of the Companies Act 1985

To the Registrar of Companies
(Address overleaf - Note 6)

For official use

Company number



3322659

Name of company

* ROSANTO PHARMACEUTICAL LIMITED (the "Chargor")

Date of creation of the charge

30 September 2008

Description of the instrument (if any) creating or evidencing the charge (note 2)

A security agreement dated 30 September 2008 between, amongst others, the
Chargor and the Collateral Agent (as defined below) (the "Deed")

Amount secured by the mortgage or charge

All present and future Obligations (as defined in Continuation Sheet 1)
(whether actual or contingent and whether owed jointly or severally or in
any other capacity whatsoever), except for any obligation or liability
which, if it were so included, would result in the Deed contravening any
law (including section 151 of the Companies Act 1985) (the "Secured
Liabilities")

Names and addresses of the mortgagees or persons entitled to the charge

Fortress Credit CO LLC of 1345 Avenue of the Americas, 46th Floor New York,
New York 10105, United States (the "Collateral Agent")

Postcode

Presentor's name address and
reference (if any)

Allen & Overy LLP
One Bishops Square
London

E1 6AD

Time critical reference

BK 9958894

For official Use (06/2005)

Mortgage Section

THURSDAY



AUCWG40W

A76

16/10/2008

278

COMPANIES HOUSE

See Continuation Sheet 1

Please do not
write in
this margin

**Please complete
legibly, preferably
in black type, or
bold block
lettering**

Particulars as to commission allowance or discount (note 3)

Signed *Allen & Overly LLP*

Date *15/10/08*

On behalf of ~~XXXXXXXX~~ [mortgagee/chargee] †

**A fee is payable
to Companies
House in
respect of each
register entry
for a mortgage
or charge
(See Note 5)**

† delete as
appropriate

Notes

- 1 The original instrument (if any) creating or evidencing the charge, together with these prescribed particulars correctly completed must be delivered to the Registrar of Companies within 21 days after the date of creation of the charge (section 395) If the property is situated and the charge was created outside the United Kingdom delivery to the Registrar must be effected within 21 days after the date on which the instrument could in due course of post, and if dispatched with due diligence, have been received in the United Kingdom (section 398) A copy of the instrument creating the charge will be accepted where the property charged is situated and the charge was created outside the United Kingdom (section 398) and in such cases the copy must be verified to be a correct copy either by the company or by the person who has delivered or sent the copy to the Registrar The verification must be signed by or on behalf of the person giving the verification and where this is given by a body corporate it must be signed by an officer of that body A verified copy will also be accepted where section 398(4) applies (property situate in Scotland or Northern Ireland) and Form No 398 is submitted
- 2 A description of the instrument, eg "Trust Deed", "Debenture", "Mortgage", or "Legal charge", etc, as the case may be, should be given
- 3 In this section there should be inserted the amount or rate per cent of the commission, allowance or discount (if any) paid or made either directly or indirectly by the company to any person in consideration of his,
 - (a) subscribing or agreeing to subscribe, whether absolutely or conditionally, or
 - (b) procuring or agreeing to procure subscriptions, whether absolute or conditional,for any of the debentures included in this return The rate of interest payable under the terms of the debentures should not be entered
- 4 If any of the spaces in this form provide insufficient space the particulars must be entered on the prescribed continuation sheet
- 5 A fee of £13 is payable to Companies House in respect of each register entry for a mortgage or charge Cheques and Postal Orders must be made payable to **Companies House**
- 6 The address of the Registrar of Companies is **Companies House, Crown Way, Cardiff CF14 3UZ**

COMPANIES FORM 395 CONTINUATION SHEET 1

SHORT PARTICULARS OF ALL THE PROPERTY MORTGAGED OR CHARGED

1. CREATION OF SECURITY

1.1 General

Pursuant to the Deed

- (a) all the Security
 - (i) is created in favour of the Collateral Agent,
 - (ii) is security for the payment, discharge and performance of all the Secured Liabilities, and
 - (iii) is made with full title guarantee in accordance with the Law of Property (Miscellaneous Provisions) Act 1994,
- (b) the Collateral Agent holds the benefit of the Deed on trust for the Secured Parties,
- (c) the fact that no or incomplete details of any Security Asset are inserted in schedule 2 to the Deed or in the schedule to any Deed of Accession (if any) by which any chargor became party to the Deed does not affect the validity or enforceability of the Security

1.2 Construction

- (a) The terms of the Loan Document and of any side letters between any parties in relation to any Loan Document (as the case may be) are incorporated in the Deed to the extent required to ensure that any purported disposition of any freehold or leasehold property contained in the Deed is a valid disposition in accordance with section 2(1) of the Law of Property (Miscellaneous Provisions) Act 1989,
- (b) If the Collateral Agent considers that an amount paid to any Secured Party under a Loan Document is capable of being avoided or otherwise set aside on the liquidation or administration of the payer or otherwise, then that amount will not be considered to have been irrevocably paid for the purposes of the Deed,
- (c) A reference to a Security Asset includes
 - (i) any part of that Security Asset,
 - (ii) any proceeds of that Security Asset, and
 - (iii) any present and future assets of that type
- (d) Unless a contrary indication appears in the Deed, a reference in the Deed to
 - (i) a "Collateral Agent", any "Loan Party", any "Secured Party", any "Lender", any "Party" or any other person shall be construed so as to include its successor in title, permitted assigns and permitted transferees, and

- (ii) "assets" includes present and future properties, revenues and rights of every description,
- (e) Any definition of or reference to any agreement, instrument or other document (including, without limitation, any Loan Document) shall be construed as referring to such agreement, instrument or other document as amended or otherwise modified from time to time

1.3 Land

Pursuant to the Deed

- (a) the Chargor charged
 - (i) by way of a first legal mortgage all estates or interests in any freehold or leasehold property owned by it and all rights under any licence or other agreement or document which gives the Chargor a right to occupy or use property, and
 - (ii) (to the extent that they are not the subject of a mortgage created under the Deed as described in subparagraph (i) above) by way of first fixed charge all estates or interests in any freehold or leasehold property owned by it and all rights under any licence or other agreement or document which gives the Chargor a right to occupy or use property, and
- (b) a reference in the Deed to any freehold or leasehold property includes
 - (i) all buildings, erections, fixtures and fittings (including trade fixtures and fittings) and fixed plant and machinery on that property owned by the Chargor, and
 - (ii) the benefit of any covenants for title given or entered into by any predecessor in title of the Chargor in respect of that property and any moneys paid or payable in respect of those covenants

1.4 Investments

Pursuant to the Deed

- (a) the Chargor charged by way of a first legal mortgage
 - (i) all shares in any Loan Party owned by it or held by any nominee on its behalf, this includes any specified in part 2 of schedule 2 to the Deed (as reproduced in Annex 1 to this Continuation Sheet 1) opposite its name, and
 - (ii) all other shares, stocks, debentures, bonds, warrants, coupons or other securities and investments (including all Cash Equivalents Investment) owned by it or held by any nominee on its behalf, and
- (b) a reference in the Deed to any share, stock, debenture, bond, warrant, coupon or other security or investment includes
 - (i) any dividend, interest or other distribution paid or payable,
 - (ii) any right, money or property accruing or offered at any time by way of redemption, substitution, exchange, bonus or preference, under option rights or otherwise,

- (iii) any right against any clearance system, and
- (iv) any right under any custodian or other agreement,

in relation to that share, stock, debenture, bond, warrant, coupon or other security or investment

1.5 Plant and machinery

Pursuant to the Deed, the Chargor charged by way of a first fixed charge all Plant and Machinery owned by it and its interest in any Plant and Machinery in its possession

1.6 Credit balances

Pursuant to the Deed, the Chargor charged by way of a first fixed charge all of its rights in respect of any amount standing to the credit of any bank or other account (including a current account) it has with any person and the debt represented by that account

1.7 Insurances

Pursuant to the Deed

- (a) the Chargor assigned absolutely, subject to a proviso for reassignment on redemption, all amounts payable to it under or in connection with each of its Insurances set out in schedule 6 01(v) to the Loan Agreement (as reproduced in Annex 4 to this Continuation Sheet 1) and all of its rights in connection with those amounts,
- (b) to the extent that they are not effectively assigned under the Deed as referred to in paragraph (a) above, the Chargor charged by way of first fixed charge all amounts and rights described in paragraph (a) above,
- (c) the Chargor charged by way of first fixed charge all amounts payable to it under or in connection with each of its other Insurances and all of its rights in connection with those amounts, and
- (d) a reference to any amounts described above excludes all amounts received or receivable under or in connection with any third party liability Insurance and required to settle a liability of a Loan Party to a third party

1.8 Other contracts

Pursuant to the Deed

- (a) the Chargor assigned absolutely, subject to a proviso for re-assignment on redemption, all of its rights in respect of
 - (i) its Relevant Contracts,
 - (ii) any letter of credit issued in its favour, and
 - (iii) any bill of exchange or other negotiable instrument held by it,
- (b) to the extent that any right described in paragraph (a) above is not assignable or capable of assignment, the assignment of that right purported to be effected by the Deed shall operate as

an assignment of any damages, compensation, remuneration, profit, rent or income which the Chargor may derive from that right or be awarded or entitled to in respect of that right, and

- (c) to the extent that they do not fall within any other provision of the Deed and are not effectively assigned under the Deed as described in paragraph (a) or (b) above, the Chargor charged by way of first fixed charge all of its rights under each agreement and document to which it is a party

1.9 Intellectual property

Pursuant to the Deed, the Chargor charged by way of a first fixed charge all of its rights in respect of any Intellectual Property, this includes any specified in part 5 of schedule 2 to the Deed (as reproduced in Annex 3 to this Continuation Sheet 1) opposite its name

1.10 Miscellaneous

Pursuant to the Deed, the Chargor charged by way of a first fixed charge

- (a) any beneficial interest, claim or entitlement it has to any assets of any pension fund,
- (b) its goodwill,
- (c) the benefit of any authorisation (statutory or otherwise) held in connection with its business or the use of any Security Asset,
- (d) the right to recover and receive compensation which may be payable to it in respect of any authorisation referred to in paragraph (c) above, and
- (e) its uncalled capital

1.11 Floating charge

Pursuant to the Deed

- (a) the Chargor charged by way of a first floating charge all of its assets whatsoever and wheresoever not otherwise effectively mortgaged, charged or assigned under the Deed,
- (b) except as otherwise provided in the Deed, the Collateral Agent may by notice to the Chargor convert the floating charge created by the Chargor under the Deed into a fixed charge as regards any of the Chargor's assets specified in that notice, if
 - (i) an Event of Default is continuing,
 - (ii) the Collateral Agent (acting in good faith) considers those assets to be in danger of being seized or sold under any form of distress, attachment, execution or other legal process or to be otherwise in jeopardy, or
 - (iii) the Chargor fails to comply, or takes or threatens to take any action which, in the reasonable opinion of the Collateral Agent, is likely to result in it failing to comply with its obligations under paragraph (a) of clause 4 (Restrictions on dealing) of the Deed,

- (c) the floating charge created under the Deed may not be converted into a fixed charge solely by reason of
 - (i) the obtaining of a moratorium, or
 - (ii) anything done with a view to obtaining a moratorium,under section 1A to the Insolvency Act 1986,
- (d) the floating charge created under the Deed will (in addition to the circumstances in which the same will occur under general law) automatically convert into a fixed charge over all of the Chargor's assets
 - (i) if an administrator is appointed or the Collateral Agent receives notice of an intention to appoint an administrator, or
 - (ii) on the convening of any meeting of the members of the Chargor to consider a resolution to wind the Chargor up (or not to wind the Chargor up),
- (e) the floating charge created under the Deed is a **qualifying floating charge** for the purpose of paragraph 14 of Schedule B1 to the Insolvency Act 1986, and
- (f) the giving by the Collateral Agent of a notice under the Deed as described in paragraph (b) above in relation to any asset of the Chargor will not be construed as a waiver or abandonment of the Collateral Agent's rights to give any other notice in respect of any other asset or of any other right of any other Secured Party under the Deed or the Loan Agreement or any other Loan Document

2. RESTRICTIONS ON DEALINGS

Pursuant to the Deed, the Chargor may not

- (a) create or allow to exist any Lien on any of its assets, or
- (b) either in a single transaction or in a series of transactions and whether related or not and whether voluntarily or involuntarily dispose of all or any part of its assets,

unless permitted under the Loan Agreement

3. WHEN SECURITY BECOMES ENFORCEABLE

3.1 Timing

Under the Deed, the Security will become immediately enforceable if an Event of Default occurs and an Event of Default is continuing

3.2 Enforcement

After the Security has become enforceable, the Collateral Agent may in its absolute discretion enforce all or any part of the Security in any manner it sees fit or as the Required Lenders direct

4. FURTHER ASSURANCES

Pursuant to the Deed, the Chargor must, at its own expense, take whatever action the Collateral Agent or a Receiver may require for

- (a) creating, perfecting or protecting any security intended to be created by or pursuant to the Deed,
- (b) facilitating the realisation of any Security Asset,
- (c) facilitating the exercise of any right, power or discretion exercisable by the Collateral Agent or any Receiver or any of their respective delegates or sub-delegates in respect of any Security Asset, or
- (d) creating and perfecting security in favour of the Collateral Agent (equivalent to the security intended to be created by the Deed) over any assets of the Chargor located in any jurisdiction outside England and Wales

This includes

- (i) the re-execution of the Deed,
- (ii) the execution of any legal mortgage, charge, transfer, conveyance, assignment or assurance of any property, whether to the Collateral Agent or to its nominee, and
- (iii) the giving of any notice, order or direction and the making of any filing or registration,

which, in any such case, the Collateral Agent may think expedient

5. DEFINITIONS

The terms used in this Companies House form 395 have the meaning set out below

Account means, any "deposit account" or "securities account" as such terms are defined in the UCC, including without limitation, the Concentration Accounts,

Account Control Agreement means, with respect to any Account, an agreement, in form and substance satisfactory to the Collateral Agent, which (i) effectively gives "control" (as defined in the UCC) to the Collateral Agent in such Account and all investment property, funds or other Property held or maintained therein, and (ii) grants the Collateral Agent a valid, perfected and first priority Lien over such Account and all such investment property, funds or other Property,

Account Debtor means, any Person who is or may become obligated under, with respect to, or on account of, an Account Receivable,

Account Receivable means, collectively, any "account" (as that term is defined in the UCC) and any and all "supporting obligations" (as that term is defined in the UCC) in respect of such account,

Acquired Products means, collectively, Flammazine and Flammacerum and any other pharmaceutical products, if any, acquired pursuant to the Acquisition Agreement,

Acquisition Document means, the Product Transfer Agreement, dated as of April 10, 2008, by and between the Borrower and Solvay, the form, terms and conditions of which shall be satisfactory to the Administrative Agent, as amended on the Closing Date pursuant to the Tripartite Agreement,

Additional Chargor means, a Loan Party which becomes a Chargor by executing a Deed of Accession,

Administrative Agent means, Fortress Credit Co LLC as the administrative agent for the Secured Parties,

Administrative Agent Account means, the account identified at schedule 1 01 to the Loan Agreement into which the Borrower shall make all payments to the Administrative Agent for the benefit of the Agents and the Lenders under the Loan Agreement and the other Loan Documents,

Affiliate means, as applied to any specified Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such specified Person. For the purposes of this definition, "control" (including, with correlative meanings, the terms "controlling", "controlled by" and "under common control with"), as applied to any specified Person, means the possession, directly or indirectly, of the power to vote ten percent (10 0%) or more of the Voting Securities of such specified Person or otherwise to direct or cause the direction of the management and policies of such specified Person or otherwise to direct or cause the direction of the management and policies of such specified Person, whether through the ownership of Voting Securities or by contract or otherwise, provided, however, when "Affiliate" is used in connection with any Loan Party, each Lender and each Agent-Related Person and each of their respective affiliates (other than any Loan Party) shall be excluded from the definition of "Affiliate",

Agents means, the Administrative Agent and the Collateral Agent,

Agent-Related Person means, the Administrative Agent and any successor agents thereto (in accordance with the terms of the Loan Agreement), and the Collateral Agent and any successor agents thereto (in accordance with the terms of the Loan Agreement), together with their respective Affiliates, and the officers, directors, employees, counsel, agents, and attorneys-in-fact of such Persons and their respective Affiliates,

Applicable Law means, as to any person, the Governing Documents of such Person, and any law, rule, regulation, directive, statute, code, ordinance or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its Property or to which such Person or any of its Property is otherwise subject (including, without limitation, the Companies Act, the Exchange Act, Regulation T, Regulation U and Regulation X or each law, rule or regulation or determination equivalent, analogous or similar thereto) and any certificate of occupancy, zoning ordinance, building, environmental or land use requirement or Permit or environmental, labour, employment, occupational safety or health law, rule or regulation or determination equivalent, analogous or similar thereto,

Authorised Officer means, relative to any Person, those of its officers or employees whose signatures and incumbency shall have been certified to the Administrative Agent, the Collateral Agent and the Lenders pursuant to section 2 05 or section 5 01(a)(11) of the Loan Agreement,

Board of Directors means, relative to any Person, the board of directors, board of managers or other equivalent governing body of such Person,

Borrower means, York Pharma Plc (company number 4466213),

Business means, the business of researching, developing, manufacturing, testing, labelling, packaging, storing, purchasing, marketing, distributing and selling the Products or any of them,

Business Day means a day, which is not a Saturday or Sunday or a legal holiday and on which banks are not required or permitted by law or other governmental action to close (i) in NY and (ii) in the case of a Business Day which relates to EURIBOR, in Brussels,

Capital Lease means, with respect to any person, any lease of (or other agreement conveying the right to use) any real or personal property by such person that, in accordance with IFRS, is accounted for as a capital lease on the balance sheet of such Person,

Capital Securities means, with respect to any Person, any stock, shares, interests, participations, partnership or other equity interests (including warrants), voting trust certificates, bonds, debentures, notes or other evidences of indebtedness (whether secured or unsecured, convertible, subordinated or otherwise) or in general any other instruments commonly known or referred to as "Investments" (however designated, whether voting or non-voting) of such Person's capital, including, without limitation, any securities convertible into or exchangeable for any of the foregoing or any warrants, options or other rights to subscribe to, or for the purchase or acquisition of, any of the foregoing, whether now outstanding or issued after the Closing Date, provided, that "Capital Securities" shall not include any note or other instrument evidencing any of the Obligations,

Cash Equivalent Investment means, at any time, (i) any evidence of debt, maturing not more than one year after such time, issued or guaranteed by the federal governments of the United States or any agency thereof, (ii) commercial paper, maturing not more than one year from the date of issue, or corporate demand notes, in each case rated at least A-1 by Standard & Poor's Ratings Group (a Division of The McGraw-Hill Companies, Inc) or P-1 by Moody's Investors Service, Inc , (iii) any certificate of deposit (or time deposits represented by such certificates of deposit) or banker's acceptance, maturing not more than one year after such time, or overnight federal funds transactions that are issued or sold by a commercial banking institution that is a member of the Federal Reserve and has a combined capital and surplus and undivided profits of not less than \$500,000,000, and (iv) any repurchase agreement entered into with any commercial banking institution of the stature referred to in (iii) above which (a) is secured by a fully perfected security interest in any obligation of the type described in (i) to (iii) above and (b) has a market value at the time such repurchase agreement is entered into of not less than 100% of the repurchase obligation of such commercial banking institution thereunder,

Closing Date means, the date on which all of the conditions precedent set out at section 5.01 of the Loan Agreement have been satisfied or waived in writing and the Loans have been funded and received by the Borrower pursuant to the requirements set out at section 2.01(c) of the Loan Agreement,

Closing Date Certificate means, a closing date certificate, executed and delivered by an Authorised Officer of the Borrower and dated as of the Closing Date, in substantially the form of Exhibit G attached to the Loan Agreement,

Collateral means, all Property subject to any Lien purported to be created by any Collateral Document or any other Loan Document, including, without limitation, any Collections or other amounts held in any Concentration Account,

Collateral Agent means, Fortress Credit Co LLC as agent and trustee for the Secured Parties,

Collateral Documents means, each of the Security Agreements, each Filing covering any Loan Party or any other Person or any Property of any Loan Party or any other Person, each Account Control Agreement, and each and every other agreement document or instrument pursuant to which any Loan Party or any other Person grants a Lien to the Collateral Agent to secure the Obligations,

Collections means, all cash, checks, notes, instruments, and other items of payment (including insurance and condemnation proceeds, cash proceeds of sales and other voluntary or involuntary dispositions of property, rental proceeds, and tax refunds),

Companies Act means the U.K. Companies Act 1985, as amended,

Concentration Accounts has the meaning ascribed to such term as set out at section 11.02 of the Loan Agreement,

Concentration Account Agreement means, an Account Control Agreement, in form and substance satisfactory to the Collateral Agent, by and among the Concentration Account Bank, the Borrower and the Collateral Agent delivered in connection with the Borrower's cash management system under the Loan Agreement in accordance with that set out at section 11.02 of the Loan Agreement,

Concentration Account Bank means, HSBC, or such other bank or financial institution which is selected by the Borrower and which is reasonably acceptable to each Agent,

Contingent Obligation means, with respect to any Person, any obligation of such Person guaranteeing or intended to guarantee any Indebtedness (the "primary obligation") of any other Person (the "primary obligor") in any manner, whether directly or indirectly, including, without limitation, (i) the direct or indirect guaranty, endorsement (other than for collection or deposit in the ordinary course of business), co-making, discounting with recourse or sale with recourse by such Person of the obligation of such primary obligor, (ii) the obligation to make take-or-pay or similar payments, if required, regardless of non-performance by any other party or parties to an agreement, (iii) any of such Person, whether or not contingent, (A) to purchase any such primary obligation or any Property constituting direct or indirect security therefore, (B) to advance or supply funds (1) for the purchase or payment of any such primary obligation or (2) to maintain working capital or equity capital of such primary obligor or otherwise to maintain the net worth or solvency of such primary obligor, (C) to purchase Property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of such primary obligor to make payment of such primary obligation or (D) otherwise to assure or hold harmless the holder of such primary obligation against loss in respect thereof, provided, however, that the term "Contingent Obligation" shall not include any products warranties extended in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determinable amount of the primary obligation with respect to which such Contingent Obligation is made (or, if less, the maximum amount of such primary obligation for which such Person may be liable pursuant to the terms of the instrument evidencing such Contingent Obligation) or, if not stated or determinable, the maximum reasonably anticipated liability with respect thereto (assuming such Person is required to perform thereunder), as determined by such Person in good faith,

Contractual Obligation means, as applied to any Person, any contract, agreement or undertaking, including, without limitation, any indenture, mortgage, deed of trust, security agreement, pledge agreement, guaranty or other instrument to which such Person is party or by which it or any of its Property is bound or subject, including, without limitation, such Person's Governing Documents,

Convertible Debt Deed means, the Deed Poll Constituting \$6,000,000 Convertible Subordinated Unsecured Loan Notes (including all schedules and exhibits thereto), dated on or about 30 September 2008, by and among the Borrower and the Loan Noteholders (as defined therein) in substantially the same form of Exhibit N attached to the Loan Agreement,

Convertible Debt Documents means, collectively, (i) the Convertible Debt Deed, (ii) the Warrant Instrument for Series "B" Warrants 2008 in the Borrower, executed and delivered by the Borrower on the Closing Date, in substantially the form of Exhibit O attached to the Loan Agreement, (iii) the

Solvay Convertible Debt Deed, (iv) any notes or similar instruments issued in connection therewith, and (v) all other documents, agreements or instruments issued pursuant to or in connection with the foregoing,

Copyright Security Agreement means, any copyright security agreement executed by any Loan Party in favour of the Collateral Agent,

Deed of Accession means, a deed substantially in the form of that set out at schedule 6 to the Security Agreement,

Default means, (i) any Event of Default or (ii) any event or occurrence which, with the giving of notice or the lapse of time, or both, would constitute an Event of Default,

Drawbridge means, Drawbridge Special Opportunities Fund LP, a Delaware limited partnership,

EURIBOR means, with respect to each Interest period, (i) the applicable Screen Rate or (ii) if no Screen Rate is available for such Interest Period, the arithmetic mean (rounded upward to four (4) decimal places) of the rates as quoted to the Administrative Agent at its request by at least two (2) major reference banks in the European interbank market selected by the Administrative Agent as the EURIBOR rate quoted to leading banks in the European interbank market, as of 11 00 a.m. (Brussels time) on the Interest Rate Determination Date for the offering of deposits in Euros for a period of one (1) month,

Event of Default means, any of the occurrences set forth in section 10.01 of the Loan Agreement after the expiration of any applicable grace or cure period and the giving of any applicable notice, in each case as expressly provided in section 10.01 of the Loan Agreement,

Exchange Act means, the U.S. Securities Exchange Act of 1934, as amended from time to time, and any successor law, rule or regulation and interpretations thereof promulgated by the SEC,

Federal Reserve means, the Federal Reserve System of the United States or any successor thereto,

Federal Reserve Board means, the Board of Governors of the Federal Reserve or any Governmental Authority succeeding to its functions,

Fee Letter means, the confidential fee letter, dated on or about 30 September 2008 between the Borrower and the Administrative Agent,

Filings means, UCC financing statements or equivalent, analogous or similar instruments or documents as may be necessary or required by any Governmental Authority or any Applicable Law in order to perfect or otherwise register any Liens granted under the Loan Agreement or under any other Loan Document in any Collateral,

Germany means, the Federal Republic of Germany,

Governmental Authority means, the government of the United States, the United Kingdom or any other nation or country, or of any political subdivision thereof, whether federal, state or local, and any agency (including, without limitation, any Regulatory Agencies), authority, instrumentality, regulatory body, patent and trademark office, intellectual property office or registry (including without limitation, the United States Patent and Trademark Office, the United Kingdom Intellectual Property Office and OHIM), court, central bank (including, without limitation, the Federal Reserve, the Bank of England and the European Central Bank or any successors thereto) or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of

or pertaining to government (including, without limitation, any supra-national bodies such as the European Union or any successor thereto),

Governing Documents means, relative to any Person, as applicable, its certificate of incorporation, charter, constitution, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement, memorandum of association, articles of association, members register, shareholders lists, excerpt from the commercial register (in the case of any Person incorporated in Germany) and all shareholder agreements, voting trusts and similar arrangements applicable to any of such Person's Capital Securities and any agreement or document analogous to any of the foregoing,

Hedging Agreement means, any and all transactions, agreements, or documents now existing or hereafter entered into by the Borrower or any of its Subsidiaries under which the counterparty of such agreement is (or at the time such agreement was entered into, was) a Lender, an Affiliate of a Lender or any other Person approved in writing by the Administrative Agent, which provide for an interest rate, credit, commodity or equity swap, cap, floor, collar, forward foreign exchange transaction, currency swap, cross currency rate swap, currency option, or any combination of, or option with respect to, these or similar transactions, for the purpose of hedging the Borrower's or such Subsidiary's (as the case may be) exposure to fluctuations in interest or exchange rates, loan, credit exchange, security or currency valuations or commodity prices,

Hedging Obligation means, with respect to any Person, any liability of such Person under any Hedging Agreement,

IFRS means, international accounting standards within the meaning of the IAS Regulation 1606/2002 in effect on, and to the extent used by the Borrower in the preparation of the unaudited financial statements of the Borrower and its Subsidiaries for the 6-month period ended, March 31, 2008,

Indebtedness means, as applied to any person at any time, (i) all indebtedness, obligations or other liabilities of such Person (A) for borrowed money (including Subordinated Debt) or evidenced by Notes, debt securities, debentures, acceptances, notes or other similar instruments, and any accrued interest, fees and charges relating thereto, (B) under profit payment agreement or in respect of obligations to redeem, repurchase or exchange any Capital Securities of such Person or to pay dividends in respect of any stock, (C) with respect to letters of credit issued and banker's acceptances issued for such Person's account, (D) to pay the deferred purchase price of Property or services (including, without limitation, the Solvay Second Instalment Payment), except accounts payable, accrued expenses and deferred revenue arising in the ordinary course of business, (E) in respect of Capital Leases which have been or should be recorded as liabilities on a balance sheet of such person in accordance with IFRS, (F) which are Contingent Obligations or (G) which are Hedging Obligations of such Person, (ii) all indebtedness, obligations or other liabilities of such Person or others secured by a Lien on any Property of such Person, whether or not such indebtedness, obligations or liabilities are assumed by such Person, all as of such time, (iii) all preferred stock subject (upon the occurrence of any contingency or otherwise) to mandatory redemption on or prior to the first anniversary of the Maturity Date, (iv) all indebtedness of any partnership of which such Person is a general partner, and (v) all contingent Contractual Obligations with respect to any of the foregoing,

Insurances means, in relation to the Chargor its insurances set out in schedule 6 01(v) to the Loan Agreement (as reproduced at Annex 4 to this Continuation Sheet 1),

Intellectual Property means, all (i) rights in inventions, patents, copyrights, mask works, design rights, rights in computer software, trade secrets, rights in confidential information, rights in know-

how, trademarks, service marks, trade names, trade dress, domain names, and all other intellectual property rights, in each case whether registered or unregistered, anywhere in the world, (ii) applications and registrations and rights to apply for any of the rights described in clause (i) of this sentence, and (iii) all other rights of a similar nature or having a similar effect,

Intellectual Property Security Agreements means, collectively, each Trademark Security Agreement, each Patent Security Agreement and each Copyright Security Agreement,

Interest Period means, one (1) calendar month, except with respect to the initial Interest Period, which shall commence on the Closing Date and which shall end on 30 September 2008,

Interest Rate Determination Date means, for each Interest period, the second Business Day immediately preceding the first day of such Interest Period,

Interco Subordination Agreement means, a written subordination agreement, in substantially the same form of Exhibit L attached to the Loan Agreement, relating to any Indebtedness of any Loan Party owing to any other Loan Party,

Legal Transfer Date means the date of payment in full of the second instalment by the Borrower to Solvay pursuant to the Acquisition Agreement upon which the legal ownership of the Intellectual Property listed in Part B of Annex 3 to this Continuation Sheet 1 shall pass on from Solvay to York,

Lender means, Fortress Credit Co LLC and any other Person made a party to the Loan Agreement as a "Lender" in accordance with the provisions thereof,

Lien means, any mortgage, deed of trust, charge, pledge, hypothecation, assignment, conditional sale agreement, deposit arrangement, security interest, encumbrance, lien (statutory or other), preference, priority or other security agreement or preferential arrangement of any kind or nature whatsoever in respect of any Property of a Person, whether granted voluntarily or imposed by law, and includes the interest of a lessor under a Capital Lease or under any finance lease having substantially the same economic effect as any of the foregoing and the filing of any Filing or similar notice (other than a financing statement filed by a "true" lessor pursuant to § 9-505 of the UCC), naming the owner of such property as debtor (or any equivalent designation), under the UCC or other comparable law of any jurisdiction,

Loan Agreement means, the loan agreement entered into on 30 September 2008 between, amongst others, the Chargor and the Collateral Agent,

Loan Document means, the Loan Agreement, the Notes, the Fee Letter, the Warrant Agreement, the Warrants, the Subsidiary Guaranty, the Collateral Documents, the Closing Date Certificate, each Interco Subordination Agreement, each Non-Loan Party Subordination Agreement, each Officer's Certificate, each Solvency Certificate, any Hedging Agreement and all other agreements, consents, certificates, instruments and other documents delivered pursuant to or in connection with the Loan Agreement or the transactions contemplated thereby (other than any Acquisition Document or any Convertible Debt Document),

Loan Party means, as the context may require, the Borrower or any of its Subsidiaries party to or obligated under, or which any Property subject to, any Loan Document, provided, however, that no such Subsidiary shall be deemed to be a "Loan Party" hereunder if it (i) is party to an Interco Subordination Agreement, and (ii) is not party to any other Loan Document,

Loans means, the term loans made available to the Borrower by each Lender at the Closing Date, as defined in section 2.01(a) of the Loan Agreement,

Maturity Date means, February 15, 2013,

Non-Loan Party Subordination Agreement means, a written subordination agreement, in substantially the form of Exhibit M attached to the Loan Agreement, relating to any Indebtedness of any Loan Party owing to any Subsidiary which is not a Loan Party,

Notes has the meaning ascribed to such term in section 2.03 of the Loan Agreement,

NY means, New York, New York,

Obligations means, all Loans, advances, debts, liabilities or other obligations arising under or in respect of any Loan Document owing by any Loan Party to any Secured Party, any Affiliate of any Secured Party, or any Person entitled to indemnification pursuant to section 13.03 of the Loan Agreement, of any kind or nature, present or future, whether or not evidenced by any note, guaranty or other instrument, whether or not for the payment of money, whether arising by reason of an extension of credit, loan, guaranty (including any Subsidiary Guaranty), indemnification, Hedging Obligation, foreign exchange contract or in any other manner, whether direct or indirect (including those acquired by assignment), absolute or contingent, due or to become due, now existing or hereafter arising and however acquired arising under or in connection with the transactions contemplated hereby "Obligations" includes, without limitation, all interest (including any interest that, but for the provisions of any domestic or foreign law relating to bankruptcy, insolvency, reorganisation or relief of debtors or other similar law now or hereafter in effect would have accrued), charges, expenses, fees, attorneys' fees and disbursements any other sum chargeable to the Loan Parties under the Loan Agreement, the Notes or any other Loan Document,

Officer's Certificate means, a certificate substantially in the form of Exhibit F attached to the Loan Agreement,

OHIM means, the Office of Harmonization for the Internal Market,

Ordinary Shares means, ordinary shares of £0.05 each in the equity capital of the Borrower,

Other Products means, collectively, all pharmaceutical and other products researched, developed, manufactured, used, distributed, marketed and sold (or any of those activities) by the Borrower or its Subsidiaries, from time to time, other than the Acquired Products,

Parent means, the York Pharma Plc (company number 446643),

Patent Security Agreements means, any patent security agreement executed by any Loan Party in favour of the Collateral Agent,

Permit means, any registration application, permit, approval, consent, clearance, certification, authorisation, licence, entitlement, accreditation, variance, exemption, or permission required from a Governmental Authority under any Applicable Law or granted by any Regulatory Agency,

Person means, any natural or legal person, corporation, limited partnership, general partnership, joint stock company, joint venture, association, company, trust, bank, trust company, land trust, business trust, limited liability company or other organisation, whether or not a legal entity, and any Governmental Authority,

Products means, collectively, the Acquired Products and the Other Products,

Property means, any and all interests in any kind of property or asset, whether real, personal or mixed, whether tangible or intangible,

Pro Rata Shares means, with respect to any Lender, the percentage obtained by dividing (i) the outstanding principal amount of such Lender's Loan, by (ii) the aggregate principal amount of all Lenders' Loans,

Plant and Machinery means in relation to the Chargor, any plant, machinery, computers, office equipment or vehicles designated as such by the Chargor and the Collateral Agent,

Receiver means, an administrative receiver, a receiver and manager or a receiver, in each case, appointed under the Security Agreement,

Regulation T means, Regulation T of the Federal Reserve Board or any equivalent, analogous or similar regulation of any Governmental Authority,

Regulation U means, Regulation U of the Federal Reserve Board or any equivalent, analogous or similar regulation of any Governmental Authority,

Regulation X means, Regulation X of the Federal Reserve Board or any equivalent, analogous or similar regulation of any Governmental Authority,

Regulatory Agency means, any national, supranational, federal, state, local or foreign governmental or regulatory entity that has regulatory authority over the Borrower, its Subsidiaries or their respective businesses (including, without limitation, the Business) or that is concerned with the use, control, safety, efficacy, reliability, development, manufacturing, marketing, distribution, sale or other commercial or other activities relating to any commercial or other services or products (including, without limitation, the Products) in any jurisdiction or territory and includes, without limitation, the U S Food and Drug Administration, the European Medicines Agency and any of their respective successor agencies,

Relevant Contract means in relation to the Chargor (a) any agreement specified in part 4 of schedule 2 to the Deed (as reproduced in Annex 2 to this Continuation Sheet 1) opposite its name, and (b) any other agreement designated as such by the Chargor and the Collateral Agent,

Required Lenders means, at any time, the Lenders whose Pro Rata Shares are more than fifty percent (50 0%) in the aggregate at such time,

Screen Rate means, with respect to EURIBOR for the applicable Interest Period, the percentage rate per annum determined by the Banking Federation of the European Union for Euros for the relevant Interest Period, as displayed on the appropriate page of the telerate screen selected by the Administrative Agent. If the relevant page is replaced or the service ceases to be available, the Administrative Agent (after consultation with the Borrower and the lenders) may specify another page or service displaying the appropriate rate,

SEC means, the U S Securities and Exchange Commission or any Governmental Authority succeeding to its functions,

Security means, any and all (as the context requires) Liens created, evidenced or conferred by the Deed (or by any Deed of Accession),

Security Agreements means, each pledge (including, without limitation, each financial instruments account pledge agreement and each deed of pledge) and each security agreement (including, without limitation, each Intellectual Property Security Agreement) of any kind under the laws of any jurisdiction made by one or more Loan Parties in favour of the Collateral Agent or any other Secured Party, in form and substance satisfactory to the Agents, securing any Obligations of such Loan Party,

Security Assets means, all assets of the Chargor the subject of the Deed,

Secured Parties means, collectively, (i) each Lender, (ii) each Agent, (iii) each counterparty to a Hedging Agreement (or at the time such Hedging Agreement was entered into, was) a Lender or an Agent, (iv) to the extent of any payment obligations owing to Drawbridge by any Loan Party arising from or otherwise relating to the Warrant Assignment of the Warrants, Drawbridge, and (v) each of the respective successors and permitted assigns of each of the foregoing,

Solvay means, Solvay Pharmaceuticals B V , a Dutch company having its registered office at C J van Houtenlaan 36, 1381 CP Weesp, the Netherlands,

Solvay Second Instalment Payment means, the "Second Instalment", as defined in the Tripartite Agreement,

Solvency Certificate means, as to any Person, a solvency certificate in substantially the form of Exhibit K attached to the Loan Agreement executed and delivered by the chief financial Authorised Officer of such Person,

Subordinated Debt means, (i) any Convertible Debt and (ii) any other unsecured Indebtedness of the Borrower (that is not convertible into any Capital Securities other than Ordinary Shares) which is subordinated in right of payment to the Obligations pursuant to documentation containing redemption and other prepayment events, maturities, amortization schedules, covenants, events of default, remedies, acceleration rights, subordination provisions and other material terms satisfactory to the Required Lenders,

Subsidiary means, with respect to any Person, any other Person of which more fifty percent (50 0%) of the outstanding Voting Securities of such other Person (irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon the occurrence of any contingency) is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person Unless the context otherwise specifically requires, the term "Subsidiary" shall be a reference to a Subsidiary of the Borrower,

Subsidiary Guaranty means, the Subsidiary Guaranty, in substantially the form of Exhibit J attached to the Loan Agreement, executed and delivered by an Authorised Officer of each Subsidiary of the Borrower from time to time party thereto pursuant to the terms of the Loan Agreement,

Trademark Security Agreement means, any trademark security agreement executed by any Loan Party in favour of the Collateral Agent,

Transaction Documents means, collectively, each Loan Document, each Acquisition Document and each Convertible Debt Document,

Tripartite Agreement means, the Tripartite Agreement, dated on or about 30 September 2008, among Solvay, the Borrower and Fortress Credit Co LLC,

UCC means, the Uniform Commercial Code as enacted in the State of New York, as amended from time to time,

United Kingdom means, the United Kingdom of Great Britain and Northern Ireland and its constituent states,

United States or **U.S.** means, of the United States of America, its fifty (50) states, the District of Columbia and its territories and possessions,

Vacancy Agreement means, the agreement to supply made between York Pharma (UK) Limited and Vacancy Management Company Ltd dated 7 April 2008,

Voting Securities means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the Board of Directors of such Person,

Warrants has the meaning ascribed to such term in the Warrant Agreement, and

Warrant Agreement means, the Warrant Instrument executed and delivered by the Borrower, dated on or about 30 September 2008

ANNEX 1

SHARES

Chargor	Name of company in which shares are held	Name of nominee (if any) by whom shares are held	Class of shares held	Number of shares held
York Pharma PLC	York Pharma (UK) Limited		Ordinary shares of £1 each	20,000
	Dermis Development Limited		Ordinary shares of £0 01 each	75,540
			A Ordinary shares of £0 01 each	80,000
	York Pharma (R&D) Limited		Ordinary shares of £0 01 each	1,527,177
	Rosanto Pharmaceutical Limited		Ordinary shares of £0 01 each	17,661,250
Dermis Development Limited	Crawford Healthcare Limited		Ordinary shares of £1 each	2

ANNEX 2

RELEVANT CONTRACTS

Chargor	Description
Crawford Healthcare Limited	Licence Agreement made between Strakan International Limited (1) and Crawford Healthcare Limited (2) dated 7 October 2005 (as amended by the First Amendment Agreement made between Strakan International Limited (1) and Crawford Healthcare Limited (2) dated 8 December 2006 and the First Amendment Agreement made between Strakan International Limited (1) and Crawford Healthcare Limited (2) dated 8 December 2006
York Pharma Plc	Derms Development Limited Share Purchase Agreement made between Richard James Anderson, Neil Stafford and the persons listed in schedule 1 of such agreement (1) and York Pharma Plc (2) dated 8 October 2007 (the Derms Sale and Purchase Agreement)
York Pharma Plc	the Acquisition Agreement as defined in the Loan Agreement
Derms Development Limited and Crawford Healthcare Limited	Supply and Distribution Agreement made between Ego Pharmaceuticals Pty Ltd and JJS Pharma Limited dated 10 November 2004 as amended, supplemented and novated from time to time including by a Novation Agreement made between Ego Pharmaceuticals Pty Ltd, JJS Pharma Limited and Derms Development Limited dated 31 May 2005, by a memorandum of agreement between Ego Pharmaceuticals Pty Ltd, Crawford Healthcare Limited and Derms Development Limited, and by a letter of variation dated 31 October 2007 between Ego Pharmaceuticals Proprietary Limited and Derms development Limited (the Ego Agreement)
Crawford Healthcare Limited	Toll manufacturing and supply agreement made between Crawford Healthcare Limited and Dr August Wolff Arzneimittel GmbH & Co KG dated 5 December 2006 (the Wolff Agreement)

York Pharma (UK) Limited

Agreement to supply made between York Pharma (UK) Limited and Vacancy Management Company Ltd dated 7 April 2008 (the **Vacancy Agreement**)

York Pharma Plc

Asset purchase and know how license agreement entered into between BaFuS Marketing GmbH and York Pharma Plc on 31 March 2004 (the **Abasol Agreement**)

ANNEX 3

SPECIFIC INTELLECTUAL PROPERTY

PART A

INTELLECTUAL PROPERTY OWNED BY THE CHARGORS AS AT THE DATE OF THE DEED

PATENTS AND PATENT APPLICATIONS

1. ABASOL ®

1.1 Substituted 2-Aminothiazoles (Family 1)

Proprietor York Pharma Plc

Original (superseded) Applications

Territory	Number	Filing Date
Germany	19883836184	11 Oct 1988
European	0365913	11 Oct 1989

Granted Patents

Territory	Number	Expiry Date
Austria	EP097413	11 Oct 2009
Australia	620928	24 Oct 2009
Belgium	0365913	11 Oct 2009
Canada	2001168	20 Oct 2009
Switzerland & Liechtenstein	0365913	11 Oct 2009
Germany	58906207-7	11 Oct 2009
Spain	2060711	11 Oct 2009
France	0365913	11 Oct 2009
United Kingdom	0365913	11 Oct 2009
Greece	3010565	11 Oct 2009
Italy	0365913	11 Oct 2009
Japan	2888560	20 Oct 2009
Luxembourg	0365913	11 Oct 2009

The Netherlands	0365913	11 Oct 2009
Sweden	0365913	11 Oct 2009
United States	5104879	11 Oct 2010

1.2 Substituted 2-Aminothiazoles (Family 2)

Proprietor York Pharma Plc

Original (superseded) Applications

Territory	Number	Filing Date
Germany	19883836167	24 Oct 1988
Germany	19883839758	25 Nov 1988
European	0365915	11 Oct 1989

Granted Patents

Territory	Number	Expiry Date
Austria	E104669	11 Oct 2009
Australia	622227	23 Oct 2009
Belgium	0365915	11 Oct 2009
Canada	2001167	20 Oct 2009
Switzerland& Liechtenstein	0365915	11 Oct 2009
Germany	58907502 0	11 Oct 2009
Spain	2051954	11 Oct 2009
France	0365915	11 Oct 2009
United Kingdom	0365915	11 Oct 2009
Greece	3012660	11 Oct 2009
Italy	0365915	11 Oct 2009
Japan	1911934	23 Oct 2009
Luxembourg	0365915	11 Oct 2009
The Netherlands	0365915	11 Oct 2009
Sweden	0365915	11 Oct 2009

United States

4956370

11 Oct 2009

1.3 Use of aminothiazoles for treating wounds and skin (Family 3)

Proprietor York Pharma Plc

Original (superseded) Applications

Territory	Number	Filing Date
Germany	1997 1000795	13 Jan 1997
International	WO 98/30212	7 Jan 1998

Granted Patents

Territory	Number	Expiry Date
Austria	0967980	7 Jan 2018
Belgium	0967980	7 Jan 2018
Germany	59808165-8	7 Jan 2018
Luxembourg	0967980	7 Jan 2018
Monaco	0967980	7 Jan 2018
Switzerland& Liechtenstein	0967980	7 Jan 2018
United States	6204272	7 Jan 2018

Pending Application

Territory	Number	Filing Date
Japan	530530-98	7 Jan 1998

1.4 Antimycotic nail polish formulations comprising substituted 2-aminothiazoles as an active substance (Family 4)

Proprietor York Pharma Plc

Original (superseded) Applications

Territory	Number	Filing Date
Germany	2003 1041944 1	1 Sept 2003
International	WO 05/034956	24 Jan 2004

Granted Patents

Territory	Number	Expiry Date
Belgium	1682146	24 Jan 2024
France	1682146	24 Jan 2024
Germany	50 2004 005 924 4	24 Jan 2024
Italy	1682146	24 Jan 2024
Spain	1682146	24 Jan 2024
Switzerland& Liechtenstein	1682146	24 Jan 2024
Turkey	1682146	24 Jan 2024
United Kingdom	1682146	24 Jan 2024

Pending Applications

United States	10/554,703	24 Jan 2004
Japan	2006-525635	24 Jan 2004

1.5 Novel Formulation (Family 19)

Proprietor: York Pharma Plc

Pending Application

Territory	Number	Filing Date
United Kingdom	0720716 0	23 Oct 2007

2. SABAREP ®

2.1 Improvements in Pharmaceutical Compositions – 1 (Family 11)

Proprietor York Pharma Plc

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0517043 6	19 Aug 2005
International	PCT/GB2006/050250	21 Aug 2006

Pending Applications

Territory	Number	Filing Date
United States	12/063,990	21 Aug 2006
Australia	2006281204	21 Aug 2006
Canada	2,619,704	21 Aug 2006
China	200680038548 9	21 Aug 2006
Japan	2008-526559	21 Aug 2006
Korea (South)	10-2008-7003828	21 Aug 2006
Russian Federation	2008110482	21 Aug 2006
Brazil	PI0615179-5	21 Aug 2006
Mexico	MX/a/2008/002299	21 Aug 2006
India	not yet known	21 Aug 2006
Europe*	08102961 3	21 Aug 2006

*All available European Patent Convention (EPC) contracting states were designated on filing

2.2 Improvements in Pharmaceutical Compositions – 2 (Family 13)

Proprietor York Pharma Plc

Original (superseded) Application

Territory	Number	Filing Date
United Kingdom	0617191 2	31 Aug 2006

Pending Application

Territory	Number	Filing Date
International	WO2008/025837	31 Aug 2007

2.3 Improving Skin Barrier Function (Family 22)

Proprietor York Pharma Plc

Original (superseded) Application

Territory	Number	Filing Date
------------------	---------------	--------------------

United Kingdom	0715141 8	3 Aug 2007
----------------	-----------	------------

Pending Application

Territory	Number	Filing Date
International	PCT/GB2008/050654	1 August 2008

3. VAMPEX ®

3.1 Treatment of Hyperproliferative Diseases (Family 5)

Proprietor York Pharma (R&D) Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0020351 3	17 Aug 2000
International	WO 02/15920	17 Aug 2001

Granted Patent

Territory	Number	Expiry Date
Australia	2001278632	17 Aug 2021

Pending Applications

Territory	Number	Filing Date
United States	10/085,239	17 Aug 2001
Australia	2006203668	17 Aug 2001
Canada	2419840	17 Aug 2001
Japan	2002-520841	17 Aug 2001
Europe	1318836	17 Aug 2001

All available European Patent Convention (EPC) contracting states were designated on filing

3.2 Derivatives of 18 β -Glycyrrhetic Acid (Family 12)

Proprietor York Pharma Plc

Original (superseded) Applications

Territory	Number	Filing Date
------------------	---------------	--------------------

United Kingdom	0604899 5	10 Mar 2006
United Kingdom	0624963 5	15 Dec 2006

Pending Application

Territory	Number	Filing Date
International	WO 07/105015	9 March 2007

4. VITIX ®

Skin Treatment Preparation (Family 20)

Proprietor Crawford Healthcare Ltd

Original (superseded) Application

Territory	Number	Filing Date
International	PCT/FR00/01601	9 June 2000

Granted Patents

Territory	Number	Expiry Date
Europe	1 286 679	9 June 2020
Hong Kong	3106224 2	9 June 2020
Germany	6 001 9979 7	9 June 2020
France	1286679	9 June 2020
Spain	2212758	9 June 2020

Pending Application

Territory	Number	Filing Date
United States	11/744,731	9 June 2000

5. PUVAPSORALEN ®

Pharmaceutical Formulation (Family 21)

Proprietor Crawford Healthcare Ltd.

Original (superseded) Applications

Territory	Number	Filing Date
------------------	---------------	--------------------

United Kingdom	9621480.4	15 Oct 1996
International	WO 98/16195	4 Oct 1997

Granted Patents

Territory	Number	Expiry Date
European	0 946 139	4 Oct 2017
Austria	E218323	4 Oct 2017
Belgium	0 946 139	4 Oct 2017
Denmark	0 946 139	4 Oct 2017
Germany	69713143 2	4 Oct 2017
Finland	0 946 139	4 Oct 2017
France	0 946 139	4 Oct 2017
Ireland	0 946 139	4 Oct 2017
Italy	0 946 139	4 Oct 2017
Spain	2178009	4 Oct 2017
South Africa	97/9179	4 Oct 2017
Sweden	0 946 139	4 Oct 2017
Switzerland	0 946 139	4 Oct 2017
United Kingdom	2318291	4 Oct 2017

6. NATURAL DEFENSE PROSTANOID MIMETICS (NDPMS)

6.1 Improvements in Pharmaceutically Useful Compounds ("4-aza") (Family 14)

Proprietor: Rosanto Pharmaceuticals Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0218261 6	6 Aug 2002
International	WO 04/013077	6 Aug 2003

Granted Patents

Territory	Number	Expiry Date
------------------	---------------	--------------------

United States	7,183,400	6 Aug 2023
---------------	-----------	------------

Pending Applications

Territory	Number	Filing Date
Canada	CA2495030	6 Aug 2003
United States	11/059,086	6 Aug 2003
Europe	3766493 5	6 Aug 2003

6.2 Improvements in Pharmaceutical Compositions ("Thiol Adducts") (Family 15)

Proprietor Rosanto Pharmaceuticals Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0207232 0	27 Mar 2002
International	WO 03/082813	27 Mar 2003

Pending Applications

Territory	Number	Filing Date
Australia	2003224224	27 Mar 2003
United States	10/957,242	27 Mar 2003
Europe	3720667	27 Mar 2003

6.3 Improvements in Pharmaceutical Compositions (Family 16)

Proprietor. Rosanto Pharmaceuticals Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0515573.4	28 July 2005
(re-filed as 0614848 0)		
United Kingdom	0614848 0	26 July 2006

Pending Application

Territory	Number	Filing Date
------------------	---------------	--------------------

International

WO 08/012583

26 July 2007

6.4 Synthetic Method and Novel Chemical Compounds (Family 17)

Proprietor Rosanto Pharmaceuticals Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	207028 2	25 Mar 2002
International	WO 03/080552	25 Mar 2003

Granted Patent

Territory	Number	Expiry Date
United States	7,304,186	2023

6.5 Methods for Inhibiting IKK (Family 18)

Proprietor The ownership of patent family 18 is jointly held by The Regents of the University of California (Oakland, California) and Rosanto Pharmaceuticals Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United States	60/167,090	23 Nov 1999
United States	60/186,023	1 Mar 2000

Granted Patents

Territory	Number	Expiry Date
United States	6,649,654	
United States	7,053,119	2020

Pending Application

Territory	Number	Filing Date
United States	11/351,155	continuation of 10/376,470

7. REMAINING PIPELINE AND IP

7.1 Treatment of Hyperproliferative Diseases (Family 5)

See section 3.1 above for details

7.2 Diagnosis and Treatment of Disease (Family 6)

Proprietor York Pharma (R&D) Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	2000 0029225	30 Nov 2000
	2000 0029879	7 Dec 2000
International	WO 02/44736	30 Nov 2001

Granted Patent

Territory	Number	Expiry Date
Australia	2002 220855	30 Nov 2021

Pending Applications

Territory	Number	Filing Date
United States	12/016,012	30 Nov 2001
Australia	2007203279	30 Nov 2001
Canada	2430473	30 Nov 2001
Japan	2002-546227	30 Nov 2001
Korea (South)	10-2003-7007501	30 Nov 2001
Europe*	1356298	30 Nov 2001

*All available contracting states were designated on filing

7.3 Inhibitors for Inactivating Allergens (Family 7)

Proprietor York Pharma (R&D) Ltd

Original (superseded) Applications

Territory	Number	Filing Date
------------------	---------------	--------------------

United Kingdom	0125594 2	25 Oct 2001
International	WO 03/035107	24 Oct 2002

Pending Applications

Territory	Number	Filing Date
Canada	2458542	24 Oct 2002
Japan	2003-537673	24 Oct 2002
Europe*	1438069	24 Oct 2002

*All available European Patent Convention (EPC) contracting states were designated on filing

7.4 Corneodesmosin-Based Test for Inflammatory Disease (Family 8)

Proprietor York Pharma (R&D) Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0004312 5	23 Feb 2000
International	WO 01/62788	23 Feb 2001

Granted Patent

Territory	Number	Expiry Date
United States	7,329,540	22 Feb 2021 (tbc as USPTO has indicated that an additional 1-1 1/2yrs may be granted)

Pending Applications

Territory	Number	Filing Date
United States	11/947,000	23 Feb 2001
Europe*	1268776	23 Feb 2001

*All available European Patent Convention (EPC) contracting states were designated on filing

7.5 Single Nucleotide Polymorphisms of the SEEK1 Gene Associated with Psoriasis (Family 9)

Proprietor York Pharma (R&D) Ltd

Original (superseded) Applications

Territory	Number	Filing Date
United Kingdom	0103514.6	13 Feb 2001
International	WO 02/064831	13 Feb 2002

Pending Application

Territory	Number	Filing Date
United States	11/944,212	13 Feb 2002

Note Several of the pending applications listed in this schedule are divisional or continuation applications based on predecessors that have either been abandoned or proceeded to grant in their own right. The filing dates given for these divisional and continuation applications are those of the originals on which they are based.

YORK PHARMA PLC TRADE MARKS

Title	Owner	Number	Actions	Date	Status
MOLECULAR SKINCARE	York Pharma Plc	GB 2364843	Application Date	4-Jun-08	Registered
			Registration Date	13-Aug-09	
			Renewal Date	4-Jun-18	
			Class 03 Cosmetic skin care products and preparations		
			Class 05 Pharmaceutical preparations and products for the prevention and treatment of dermatological diseases and disorders, dermatological preparations and products for the prevention of skin disorders, dermatological preparations and products for the treatment of skin disorders, medicated preparations for the treatment of skin diseases and disorders, diagnostic products and preparations for medical purposes diagnostic preparations for medical use for sale in kit form		
			Class 42 Research and development of pharmaceutical preparations and products research and development of pharmaceutical preparations and products for the prevention and treatment of dermatological diseases and disorders, advisory services relating to diagnostic preparations and products		
			Class 44 Medical services, Medical services for the diagnosis of conditions of the human body medical analysis services for the diagnosis and treatment of persons		
		CTM 4166898	Application Date	3-Dec-04	Registered
			Registration Date	3-Feb-06	
			Renewal Date	3-Dec-14	
			Classes 03, 05, 42, 44 - as per GB application above		
YORK LOGO	York Pharma Plc	CTM - 4838249	Application Date	16-Jan-06	Registered
			Registration Date	23-Feb-07	
			Renewal Date	16-Jan-16	
			Class 03 Non-medicated preparations for the care of the skin, scalp body and/or hair non medicated toilet preparations non-medicated creams, oils, gels lotions, ointments powder and balms essential oils, cosmetics perfumes cleaning preparations beauty care products		
			Class 05 Medicated preparation for the care of the skin, scalp, body and/or hair, pharmaceutical and medicinal preparations and substances, dietetic preparations for medical use, veterinary preparations and substances		



ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
			biological preparations for medical and veterinary use		
			Class 42 Research and development relating to science, technology, industry and medicine		
			Class 44 Medical and veterinary services, health and beauty services, services for the care of the skin, scalp body and/or hair		
		MAP 880617	Application Date	3-Feb-06	Registered
			Registration Date	21-Jun-06	
			Renewal Date	3-Feb-16	
			Classes 03, 05, 42, 44 - as per CTM application above		
		Australian Designation	Application Date	3-Feb-06	Designated and Filed
			Classes 03 05 42 44 - as per CTM application above		
		Bahrain Designation	Application Date	3-Feb-06	Under Examination
			Classes 05 42 44 - as per CTM application above		
		Norway Designation	Application Date	3-Feb-06	Registered
			Classes 03 05, 42, 44 - as per CTM application above		
		P R China	Application Date	3-Feb-06	Under Examination
			Class 05 and 44 as per CTM application above		
		Russian Designation	Application Date	3-Feb-06	Registered
			Registration Date	24-Mar-08	
			Renewal Date	4-Feb-16	
			Only class 03 as per CTM application above		
		Serbian designation	Application Date	3-Feb-06	Designated and Filed
			Classes 03 05, 42 44 - as per CTM application above		
		Singaporean	Application Date	3-Feb-06	Registered

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
<hr/>					
		Designation	Classes 03, 05, 42, 44 - as per CTM application above		
<hr/>					
		Swiss Designation	Application Date	3 Feb-06	Under Examination
<hr/>					
			<p>Class 03 Non-medicated preparations for the care of the skin, scalp, body and/or hair, non-medicated toilet preparations non-medicated creams oils, gels, lotions, ointments powder and balms, essential oils, cosmetics, perfumes, cleaning preparations, beauty care products, all goods originating from Great Britain</p> <p>Class 05 Medicated preparation for the care of the skin, scalp, body and/or hair, pharmaceutical and medicinal preparations and substances, dietetic preparations for medical use, veterinary preparations and substances, biological preparations for medical and veterinary use, all goods originating from Great Britain</p> <p>Classes 42, 44 - as per CTM application above</p>		
<hr/>					
		Turkish Designation	Application Date	3-Feb-06	Registered
			Registration Date	10-Feb-08	
			Renewal Date	4-Feb-16	
<hr/>					
			Classes 03, 05, 44 - as per CTM application above		
<hr/>					
		US Designation	Application Date	3-Feb-06	Registered
			Registration Date	1-Apr-08	
			Renewal Date	1-Apr-18	
<hr/>					
			<p>Class 03 Non-medicated preparations for the skin, scalp, body and/or hair, hands or feet, non-medicated toiletries, non-medicated creams for application to the skin, scalp, body and/or hair, hands and feet NAMELY, BODY CREAM, SKIN CREAM, HAIR CREAM, COLD CREAM, CLEANSING CREAM SUN CREAMS AND ANTI-WRINKLE CREAM NON-MEDICATED oils and essential oils for application to the skin, scalp, body and/or hair, hands and feet, NAMELY BATH OIL, BODY OIL, COSMETIC OILS HAIR OILS, ESSENTIAL OILS FOR PERSONAL USE, MASSAGE OIL, PERFUME OIL AND SUNTAN OIL, NON-MEDICATED gels for application to the skin, scalp, body and/or hair, hands and feet, NAMELY, AFTER-SHAVE GEL BATH GEL, BEAUTY GELS, HAIR GELS SHAVING GEL STYLING GEL AND SUNTAN GELS, NON-MEDICATED ointments for THE CARE OF THE skin, scalp, body and/or hair, hands and feet NON-MEDICATED powders for the application to the skin, scalp, body and/or hair hands and feet to provide a protective and non stick barrier NON-MEDICATED balms for THE CARE OF the skin scalp, body and/or hair hands and feet, soaps, cosmetics, perfumes, cleansing preparations FOR THE SKIN, SCALP, BODY, HAIR HANDS AND/OR FEET beauty care PREPARATIONS for application to the skin, scalp body and/or hair, hands and feet</p>		

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
<p>Class 05 Medicated preparation for the care and treatment of the skin scalp, body and/or hair, hands and feet, medicinal preparations for the treatment of diseases of the skin NAMELY eczema, psoriasis acne fungal infections inflammatory skin conditions skin cancers itch, dryness redness and scaling of the skin hair loss and disorders of pigmentation dietetic foods adapted for medical use, veterinary preparations for use in both domestic and farm animals to treat conditions including but not limited to infections, parasites ringworm, liver fluke mange and associated loos of condition, biological preparations for medical and veterinary use</p> <p>Class 42 as per CTM application above</p> <p>Class 44 Veterinary services health services namely, the provision of care in the home or workplace AND wellness programs, beauty services, namely beauty salons HEALTH spa SERVICES IN THE NATURE OF COSMETIC BODY CARE SERVICES AND BEAUTY parlours, cosmetic body care services for the care and maintenance of the skin, scalp, body and/or hair, hands or feet</p>					
ABASOL	York Pharma Plc	CTM 3746633	Application Date	5-Apr-04	Registered
			Registration Date	15-Sep-05	
			Renewal Date	5-Apr-14	
<p>Class 05 Pharmaceutical preparations and substances for the treatment of fungal and mixed infections preparations for the treatment of gastrointestinal diseases excluded</p>					
		US 3175988	Application Date	6-Apr-04	Registered
			Registration Date	28-Nov-06	
			Renewal Date	28-Nov-16	
<p>Class 05 Pharmaceutical preparations and substances for dermatological, gynaecological and wound healing use</p>					
		JP 2004-32771	Application Date	7-Apr-04	Registered
		Registration No 5069103	Registration Date	10-Aug-07	
			Renewal Date	10-Aug-17	
<p>Class 05 Pharmaceutical (pharmaceutical preparations)</p>					
		India 1668587	Application Date	25-Mar-08	Pending
<p>Class 05 Pharmaceutical (pharmaceutical preparations)</p>					
ABASOL LOGO (In	York Pharma Plc	CTM 5176722	Application Date	3-Jul-06	Published Under

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
colour)			Registration Date		Opposition
			Renewal Date		
			Class 05 Pharmaceutical preparations and substances for the treatment of fungal and mixed infections, preparations for the treatment of gastrointestinal diseases excluded		
ABADOL	York Pharma Plc	2238946	Application Date	11-Jul-00	Registered
			Registration Date	15-Dec-00	
			Renewal Date	11-Jul-10	
			Class 05 Pharmaceutical preparations and substances for all human use		
ABAGEL	York Pharma Plc	CTM 5756366	Application Date	14-Mar-07	Registered
			Registration Date	19-Feb-08	
			Renewal Date	14-Mar-17	
			Update from files published for opposition (Nov 07 expiry)		
			Class 05 Pharmaceutical preparations and substances		
		MAP 919867	Application Date	26-Mar-07	Registered
			Registration Date	23-May-07	
			Renewal Date	26-Mar-17	
			Class 05 as per CTM above		
		International TM 919867	Application Date	23-Mar-07	Registered
			Registration Date	10-Jun-08	
		US designation	Renewal Date	26-Mar-17	
			Class 05 Pharmaceutical preparations and substances FOR DERMATOLOGICAL USES		
		International TM 919867	Application Date	26-Mar-07	Registered
		Japanese Designation	Registration Date	28-Mar-08	
			Class 05 Pharmaceutical preparations and substances		
SABAREP	York Pharma Plc	CTM 4941555	Application Date	6-Mar-06	Registered

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
			Registration Date	10-Apr-07	
			Renewal Date	6-Mar-16	
			Class 05 Medicated preparation for the care of the skin scalp body and/o hair pharmaceutical and medicinal preparations and substances, dietetic preparations for medical use, veterinary preparations and substances biological preparations for medical and veterinary use		
		MAP 923095	Application Date	21-Jun-07	
			Registration Date	10-Apr-07	Registered
			Class 05 Pharmaceutical preparations and substances		
		International TM 923095	Application Date	10-Apr-07	Registered
		US Designation	Registration Date	10-Jun-08	
			Renewal Date	10-Apr-17	
			Class 05 Pharmaceutical preparations and substances FOR DERMATOLOGICAL USES		
VAMPEX	York Pharma Plc	MAP 929129	Application Date	10-Apr-07	Registered
			Registration Date		
			Renewal Date	10-Apr-17	
			Class 05 Pharmaceutical preparations and substances FOR DERMATOLOGICAL USES		
		Japanese Designation	Application Date	10-Apr-07	Pending
		No 929129	Registration Date	10-Apr-08	
		United States 79/040387	Application Date	10-Apr-07	Pending/Published
SABABASE	York Pharma Plc	CTM 6394878	Application Date	25-Oct-07	Pending
			Class 05 Pharmaceutical preparations and substances		
VITIX	Crawford Healthcare Ltd	CTM 3534451	Application Date	11-Nov-03	Registered
			Registration Date	24-May-07	
			Renewal Date	11-Nov-13	
			Class 03 Topical gel aimed to the treatment of vitiligo		

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
Class 05 Topical gel aimed to the treatment of vitiligo					
		00 3033565	France		
			Application Date (word and device)	31-May-00	Registered
			Registration Date	31-May-00	
			Renewal Date	30-May-10	
Class 03 Preparations for bleaching and other substances for washing, preparations for cleaning polishing degreasing and abrading, soap perfumery essential oils, cosmetic, hair lotions dentrifices					
Class 05 Food for babies, plasters, material for dressings, teeth filing material and for borrowing dental, disinfectant pesticides, fungicides, herbicides					
		54907/2005	Switzerland		
			Application Date	14-Jun-05	Registered
			Registration Date	2-Aug-05	536187
			Renewal Date	15-Jun-15	
Class 03 Cosmetic products for the treatment of vitiligo (narrowed from dermatological use in a partial cancellation 1st May 2006)					
Class 05 Pharmaceutical preparations for treatment of vitiligo (narrowed from dermatological use in a partial cancellation 1st May 2006)					
		1351855	India		
	Word only		Application Date	19-Apr-05	Registered
			Registration Date	19-Apr-05	
			Renewal Date	19-Apr-15	
Class 03 Cosmetologic products and preparations, cosmetologic products and preparations for dermatological use					
Class 05 Pharmaceutical preparations, dermatological pharmaceutical preparations					
		914981	International Application Date	11-Jan-07	Pending
			Registration Date		
			Renewal Date		
Homebase registration France 003033565 - 31/5/00					
Class 03 Cosmetics namely pigmentation regulators					

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
			Designated states Albania, Armenia, Azerbaijan Bosnia and Herzegovina, Bulgaria, China, Cyprus, Czech Republic, Algeria Egypt, Croatia, Hungary, Iran, Kazakhstan Morocco, Macedonia, Poland, Romania, Serbia Russia Sudan, Slovenia, Slovakia, Syrian Arab Republic, Ukraine, Uzbekistan, Vietnam, Australia, Estonia Greece, Japan, Republic of Korea, Lithuania Singapore, Turkey		
		Albanian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Algerian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Armenian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Australia Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
			Update from DK 5/6/08 - trademark accepted for registration		
		Azerbaijan Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Bosnia-Herzegovina	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Bulgarian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Chinese Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
			Renewal Date	11-Jan-17	
		Croatian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Cyprus Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Czech Republic	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Egyptian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Provisional Refusal
			Registration Date		
			Renewal Date	11-Jan-17	
		Estonia Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Greek Designation	B/W Word and Device Filed in class 03	12-Jan-11	Registered
			Registration Date	12-Jan-11	
			Renewal Date	12-Jan-21	
		Hungarian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Iranian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Provisional Refusal
			Registration Date		
			Renewal Date	11-Jan-17	
		Japanese Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
		Kazakhstan Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Lithuanian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Macedonian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Moroccan Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Poland Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Romanian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Russian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Serbian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Singapore Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Slovak Republic	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
			Renewal Date	11-Jan-17	
		Slovenian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		South Korean Designation	B/W Word and Device Filed in class 03	11-Jan-07	Provisional Refusal
			Registration Date		
			Renewal Date	11-Jan-17	
		Sudanese Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Syrian Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
			E-AV with WIPO website print showing Grant of Protection (29/5/08)		
		Ukraine Designation	B/W Word and Device Filed in class 03	11-Jan-07	Provisional Refusal
			Registration Date		
			Renewal Date	11-Jan-17	
		Uzbekistan Designation	B/W Word and Device Filed in class 03	11-Jan-07	Provisional Refusal
			Registration Date		
			Renewal Date	11-Jan-17	
		Vietnamese Designation	B/W Word and Device Filed in class 03	11-Jan-07	Registered
			Registration Date	11-Jan-07	
			Renewal Date	11-Jan-17	
		Lebanon	Authorised national filing	9-Jul-08	
			Class 03 Cosmetics Cosmetics, namely self-tanning lotions creams gels, cosmetic sun tanning preparations, cosmetics namely pigmentation regulators		
		Libya	Authorised national filing	9-Jul-08	
			Class 03 Cosmetics, Cosmetics, namely self-tanning lotions, creams, gels, cosmetic sun tanning preparations,		

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
			cosmetics namely pigmentation regulators		
		Argentina	Application Date (B/W word and device)	21-Jun-06	Pending
		2720619	Class 03, Pigmentation regulating cosmetics		
		Jordan	Application Date (B/W word and device)	21-May-07	Registered
		92613	Registration Date	21-May-07	
			Renewal Date	21-May-17	
			Class 03		
		Kuwait	Application Date (B/W word and device)	27-Jan-07	Registered
			Registration Date	27-Jan-07	
			Renewal Date	21-Jan-17	
		82706	Class 03		
		Pakistan	Application Date	20-Dec-06	Provisional Refusal
		230568	Registration Date		
			Renewal Date	20-Dec-13	
			Class 03		
		Qatar	Application Date	21-Nov-07	Pending
		47784	Registration Date		
			Renewal Date	21-Nov-17	
			Class 03		
		Saudi Arabia	Application Date	4-Apr-07	
		116110	Registration Date		
			Renewal Date	4-Dec-16	
			Class 03		
		South Africa	Application Date	19-Dec-06	Pending
		200631147	Registration Date		
			Renewal Date	19-Dec-16	

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
		United Arab Emirates	Application Date	23-May-07	Pending
		95072	Registration Date		
			Renewal Date	23-May-17	
			Class 03		
VITICOLOR	Crawford Healthcare Ltd	54906/2005	Switzerland		
			Application Date	14-Jun-05	Registered
			Registration Date		536186
			Renewal Date	14-Jun-15	
			Class 03 Preparations and cosmetic preparations and dermatologic preparations for cosmetic use		
			Class 05 Pharmaceutical preparations, dermatological pharmaceutical preparations		
		1467297	India		
			Application Date	5-Jul-06	Pending
			Registration Date		
			Renewal Date		
			Class 03 Cosmetologic products and preparations, cosmetologic products and preparations for dermatological use		
			Class 05 Pharmaceutical preparations, dermatological pharmaceutical preparations		
		France to International	Authorised national filing in France, and International filing with the following designations	9-Jul-08	
			Algeria		
			Azerbaijan		
			South Korea		
			Egypt		
			United States of America		
			Russia		
			Iran		
			Kazakhstan		
			Morocco		
			Sudan		

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
<hr/>					
			Ukraine		
			Class 03 Cosmetics Cosmetics namely self-tanning lotions, creams, gels cosmetic sun tanning preparations cosmetics, namely pigmentation regulators		
<hr/>					
		Lebanon	Authorised national filing	7/9/2008	
			Class 03 Cosmetics, Cosmetics, namely self-tanning lotions, creams, gels, cosmetic sun tanning preparations cosmetics, namely pigmentation regulators		
<hr/>					
		Libya	Authorised national filing	7/9/2008	
			Class 03 Cosmetics, Cosmetics, namely self-tanning lotions, creams gels cosmetic sun tanning preparations, cosmetics, namely pigmentation regulators		
<hr/>					
PENTADERM	Crawford Healthcare Ltd	2041142	UK		
			Application Date	13-Oct-95	Registered
			Renewal Date	13-Oct-15	
			Class 05 Pharmaceutical preparations containing 5-methoxypsoralen		
<hr/>					
		Austrian Designation	Application Date	21-Sep-97	Registered
		5112/2001	Renewal Date	22-Apr-12	
			Class 05 Pharmaceutical preparations containing 5-methoxypsoralen		
<hr/>					
		French Designation	Application Date	21-Sep-97	Registered
		D 01 3125235	Renewal Date		
			Class 05 Pharmaceutical preparations		
<hr/>					
		Italian Designation	Application Date	21-Sep-97	Registered
		RM/2002/13	Renewal Date (renewed under TO/2006/3308)	21-Jan-17	987676
			Class 05 Pharmaceutical preparations		
<hr/>					
PUVASORALEN	Crawford Healthcare Ltd	1449258	UK		
			Application Date	5-Dec-90	Registered
			Renewal Date	5-Dec-07	Paid
			Class 05 Tablets and lotions included in Class 5 for medical use for treatment psoriasis and vitiligo		
<hr/>					

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
		CTM 402164	Application Date	21-Sep-97	Registered
			Renewal Date	21-Jan-17	
			Class 05 Pharmaceutical preparations, tablets and lotions for medical use for treating psoriasis and vitiligo		
RELAXIT	Crawford Healthcare Ltd	2384605	UK		
			Application Date	16-Feb-05	Registered
			Renewal Date	16-Feb-15	
			Class 05 An osmotic faecal softener administered rectally in a micro enema for the relief of constipation		
CUPLEX	Crawford Healthcare Ltd	1172576	UK		
			Application Date	1-Apr-82	Registered
			Renewal Date	1-Apr-13	
			Class 05 Pharmaceutical preparations and substances in the form of ointments or gels for the treatment of warts, corns and callouses		
		104447	Ireland		
			Application Date	6-Apr-82	Registered
			Renewal Date	5-Apr-13	
			Class 05 Pharmaceutical preparations and substances		
ZINDACLIN	Strakan International Ltd	CTM 1721745	Application Date	23-Jun-00	Registered
			Renewal Date	23-Jun-10	
	(Note Licensed to Crawford Healthcare Ltd by virtue of the 7 October 2005 and 8 December 2006 agreements between Crawford and Strakan International Ltd)				
			Class 05 Pharmaceuticals and pharmaceutical preparations medicinal preparations drugs		
			Exclusive licence granted to Crawford Healthcare by virtue of an agreement dated 8th December 2006, which was recorded against the CTM Register on 22nd February 2007		

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
Licence states that is effective in the following territories					
Austria, Belgium, Bulgaria Czech Republic Estonia, France, Germany, Greece, Hungary Ireland Latvia, Lithuania, Luxembourg, Poland Portugal Romania, Slovak Republic, Slovenia United Kingdom Azerbaijan, Belarus, Armenia, Bosnia & Herzegovina Croatia, Kazakhstan, Kyrgyzstan Georgia Moldova Russia, Turkmenistan, Macedonia, Tajikistan, Ukraine Serbia & Montenegro, USA and Uzbekistan					
<p><u>Note</u> The Marketing Authorisations for Zindaclin in Greece and Hungary have not yet been transferred to Crawford with the respective regulatory agencies</p> <p><u>Note</u> Cyprus - A side letter dated 12 March 2006 between Crawford Healthcare Limited and Strakan International Ltd (Strakan) assigned an existing License Agreement between Strakan and Medilink Pharmaceuticals Limited for the Territory of Cyprus which also granted Crawford a non-exclusive license to the unregistered mark 'Zindaclin' in the Territory The Marketing Authorisation in the Territory of Cyprus has not yet been formally transferred to Crawford with the regulatory agency</p>					
		2236795	UK		
			Application Date	23-Jun-00	Registered
			Renewal Date	23-Jun-10	
			Class 05 Pharmaceuticals and pharmaceutical preparations medicinal preparations, drugs		
		76340488	USA		
			Application Date	20-Nov-01	Registered
			Renewal Date	21-Sep-09	
			Class 05 Pharmaceuticals and pharmaceutical preparations for use in the treatment of dermatological disorders, medicinal preparations for use in the treatment of dermatological disorders, drugs for use in the treatment of dermatological disorders		
		826238	International Application Date	31-Mar-04	Registered
			Renewal Date	31-Mar-14	
			Class 05 Pharmaceuticals preparations, medicinal preparations drugs		
			Designated States where York has Licensed Rights Croatia, Russian Federation, Turkey		

ROSANTO PHARMACEUTICAL LIMITED (COMPANY NUMBER 3322659)
SECURITY AGREEMENT

Title	Owner	Number	Actions	Date	Status
<p><u>Note</u> Turkey - A side letter dated 12 March 2006 between Crawford Healthcare Limited and Strakan International Ltd (Strakan) assigned an existing License Agreement between Strakan and FARMASEL ILAC for the Territory of Turkey whilst also granting Crawford a non-exclusive license to the Turkish trademark The Marketing Authorisation in the Territory of Turkey remains in the name of FARMASEL</p>					
		Unregistered	Lebanon		
			Application Date	N/A	Not Yet Registered
			Renewal Date	N/A	
<p><u>Note</u> Lebanon - A side letter dated 12 March 2006 between Crawford Healthcare Limited and Strakan International Ltd (Strakan) assigned an existing License Agreement between Strakan and Unipharm S A L for the Territory of Lebanon whilst also granting Crawford a non-exclusive license to the unregistered trademark Zindaclin in the Territory The Marketing Authorisation in the Territory of Lebanon remains in the name of Unipharm</p>					
					Registered

PART B

INTELLECTUAL PROPERTY RIGHTS TO BE ACQUIRED BY THE CHARGORS ON THE LEGAL TRANSFER DATE

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date
FLAMMAC ERIUM	ALGERIA	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	ARGENTINA	01/03/2004	2498223	24/11/2005	2053962	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	ARMENIA	25/12/1991	470375	25/12/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	ARUBA	02/03/1988	030317	05/04/1988	11216	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	AUSTRALIA	21/03/1986	442613	18/05/1988	A442613	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	AUSTRIA	01/07/1982	470375	01/07/1982	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BANGLADESH	02/03/1992	C-4985	02/03/1992	C-4985	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BELARUS	25/12/1991	470375	25/12/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BENELUX	18/02/1982	648335	16/07/1982	378500	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BENELUX	29/08/1995	854655	29/08/1995	571485	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BOSNIA AND HERZEGOVINA	01/03/1992	470375	01/03/1992	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BRAZIL	10/09/1992	816883262	25/01/1994	816883262	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	BULGARIA	16/09/1991	470375	16/09/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	CANADA	16/07/1996	817921	01/08/1997	TMA479356	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	CHINA	27/06/1996	658039	27/06/1996	658039	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	COSTA RICA	16/11/1993	23974	19/04/1994	86674	Registration	Solvay Pharmaceuticals B V	York Pharma Plc

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date	
FLAMMAC ERIUM	CROATIA	01/12/1992	470375	01/12/1992	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	CUBA	27/06/1996	658039			Filing	Solvay Duphar B V	York Pharma Plc	
FLAMMAC ERIUM	CZECH REPUBLIC	06/06/1990	470375	06/06/1990	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	DENMARK	17/06/1996	VA03584/96	18/04/1997	VR01740/97	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	DOMINICAN REPUBLIC	23/07/2003	046827	30/10/2003	138599	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	ECUADOR	08/04/1993	38433	25/07/1994	1665/94	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	EGYPT	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	EL SALVADOR	12/05/1993	E-1642-93	30/09/1996	247LIBRO 35	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	EUROPEAN UNION	29/12/2004	4221388	06/02/2006	4221388	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	FINLAND	17/02/1994	872/94	05/12/1994	135419	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	FRANCE *	01/07/1982	O	01/07/1982	470375A	Registration	Solvay Pharma S A S	York Pharma Plc	
FLAMMAC ERIUM	GERMANY	01/07/1982	470375	01/07/1982	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	GREECE	08/02/1985	79154	17/06/1987	79154	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	GUATEMALA	20/07/1993	4626-93	10/02/1995	74338	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	HONDURAS	26/07/1993	7195/93	24/03/1994	59563	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	HUNGARY	06/06/1990	470375			Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMAC ERIUM	INDIA	02/08/1996	724624	19/05/2005	724624	Registration	Solvay Duphar B V	York Pharma Plc	In the name of Solvay Duphar B V , recordal change of name to SPBV is pending
FLAMMAC ERIUM	INDONESIA	29/07/1996	D96/15816	15/09/1997	389539	Registration	Solvay Pharmaceuticals	York Pharma Plc	Renewal is pending

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date
							B V	
FLAMMAC ERIUM	INTERNATIONAL PROCEDURE	01/07/1982	470375	01/07/1982	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	INTERNATIONAL PROCEDURE	27/06/1996	658039	27/06/1996	658039	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	INTERNATIONAL PROCEDURE	01/07/1982	O	01/07/1982	470375A	Registration	Solvay Pharma S A S	York Pharma Plc
FLAMMAC ERIUM	IRAQ	08/06/1998	36504	10/10/2001	36504	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	IRELAND	22/04/2003	2003/00728	22/04/2003	227213	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	ISRAEL	18/03/1993	86738	04/07/1995	86738	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	ITALY	06/06/1990	470375	06/06/1990	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	KAZAKSTAN	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	KENYA	05/10/1987	35744	05/10/1987	35744	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	KOREA, NORTH	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	KYRGYZSTAN	25/12/1991	470375	25/12/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	LIBYA	28/01/2007	9937			Filing	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	LIECHTENSTEIN	06/06/1990	470375			Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	MACAU	11/12/1987	02751	25/01/1988	2751-M	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	F Y R MACEDONIA	23/07/1993	470375	23/07/1993	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	MAURITIUS	23/11/1987		15/04/1988	A/28 NO 227	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	MOLDOVA, REPUBLIC OF	25/12/1991	470375	25/12/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	MONACO	06/06/1990	470375	06/06/1990	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date
FLAMMAC ERIUM	MOROCCO	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	NETHERLANDS ANTILLES	16/09/1987	D-453	02/11/1987	14581	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	NEW ZEALAND	08/07/2003	682519	08/01/2004	682519	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	NICARAGUA	08/07/1993	93-01618	26/04/1994	25574C C	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	NORWAY	18/06/1996	963758	12/06/1997	182703	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	PANAMA	03/08/1993	067204	13/06/1995	067204	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	PARAGUAY	02/10/2003	0302527 l	24/05/2004	268166	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	PERU	27/04/2004	208815	09/07/2004	98512	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	PHILIPPINES	24/11/1995	104250	13/12/1999	4-1995-106528	Registration	Solvay Duphar B V	York Pharma Plc
FLAMMAC ERIUM	PHILIPPINES	25/10/2005	4-2005-010614			Publication	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	POLAND	16/09/1991	470375	16/09/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	PORTUGAL	01/07/1982	470375	01/07/1982	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	ROMANIA	16/09/1991	470375	16/09/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	RUSSIAN FEDERATION	06/06/1990	470375	06/06/1990	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SAN MARINO	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SAUDI ARABIA	13/02/1993	20241	27/11/1993	296/13	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SERBIA	06/06/1990	470375	06/06/1990	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SLOVAKIA	01/01/1993	470375	01/01/1993	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC	SLOVENIA	01/12/1992	470375	01/12/1992	470375	Registration	Solvay Pharmaceuticals	York

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date
ERIUM		92				on	B V	Pharma Plc
FLAMMAC ERIUM	SOUTH AFRICA	26/06/1996	96/08472	26/06/1996	96/08472	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SPAIN	27/06/1996	658039	27/06/1996	658039	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SUDAN	13/02/1989	470375	13/02/1989	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	SWEDEN	18/06/1996	96-06024	04/07/1997	324024	Registration	Solvay Pharmaceuticals B V	York Pharma Plc <i>Renewal is pending</i>
FLAMMAC ERIUM	SWITZERLAND	01/07/1982	470375	01/07/1982	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	TAJIKISTAN	25/12/1991	470375	25/12/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	THAILAND	08/09/1987	342865	31/07/1989	TM64341	Registration	Solvay Pharmaceuticals B V	York Pharma Plc <i>Renewal is pending</i>
FLAMMAC ERIUM	UKRAINE	25/12/1991	470375	25/12/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	UNITED STATES	16/12/2002	76476181	29/06/2004	2857398	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	URUGUAY	17/01/1983	188127	19/01/1984	267690	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	UZBEKISTAN	01/01/1991	470375	01/01/1991	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	VENEZUELA	18/05/1993	8738-93	10/07/1995	P178517	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMAC ERIUM	VIET NAM	07/03/1994	470375	07/03/1994	470375	Registration	Solvay Pharmaceuticals B V	York Pharma Plc

*** French registration also covers:**

Overseas Departments

Guadeloupe
French Guyana
Martinique
Reunion

Overseas Territories

French Antarctic Territories

French Polynesia

New Caledonia

Wallis & Futuna

Territorial Communities

Mayotte

St -Pierre & Miquelon

Trademark	Country	Filing date	Filing number	Registration date	Registration no.	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date	
FLAMMA ZINE	ALGERIA	22/11/1991	579642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	ARGENTINA	02/04/1993	1874765	14/09/1995	1575465	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	ARGENTINA	15/09/2005	2618483			Publication	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	ARMENIA	22/11/1991	576642	25/12/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	ARUBA	02/03/1988	030318	05/04/1988	11217	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	AUSTRIA	17/08/1972	390577	28/01/1974	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	BELARUS	22/11/1991	576642	25/12/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	BENELUX	13/03/1972	590704	29/08/1972	309877	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	BOSNIA AND HERZEGOVINA	17/08/1972	390577	01/03/1992	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	BRAZIL	10/09/1992	816883270	12/07/1994	816883270	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	Renewal is pending
FLAMMA ZINE	BULGARIA	17/08/1972	390577	16/09/1991	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	CHINA	17/08/1972	390577	16/09/1991	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	CHINA	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	CONGO, DRC	05/05/1983	NP/86/EXT/83	05/05/1983	0499/83	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	Renewal is pending
FLAMMA ZINE	CROATIA	17/08/1972	390577	01/12/1992	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	CYPRUS	13/10/1983	24207	10/11/1984	24207	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	CZECH REPUBLIC	17/08/1972	390577	16/09/1991	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	DOMINICAN REPUBLIC	23/07/2003	046828	30/10/2003	138600	Registration	Solvay Pharmaceuticals	York Pharma Plc	

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date	
							B V		
FLAMMA ZINE	EGYPT	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	FRANCE *	17/08/1972	390577	17/08/1972	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	GERMANY	17/08/1972	390577	28/01/1974	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	GHANA	12/10/1987	23946	12/10/1987	23946	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	GREECE	03/07/1972		17/05/1977	48688	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	GUATEMALA	20/07/1993	4625-93	08/12/1994	74269	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	HAITI	07/04/2005	000342	28/09/2005	336REG150	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	HONDURAS	26/07/1993	7196/93	24/03/1994	59564	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	HUNGARY	17/08/1972	390577	16/09/1991	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	INDIA	20/09/1972		20/09/1972	282973	Registration	Philips Duphar B V	York Pharma Plc	Recordal change of name to SPBV is pending Renewal is pending
FLAMMA ZINE	INDONESIA	26/08/1982	171508	31/03/1983	171508	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	INTERNATIONAL PROCEDURE	22/11/1991	576642	22/11/1991	576642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	INTERNATIONAL PROCEDURE	17/08/1972	390577	17/08/1972	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	IRAQ	19/01/1978		24/12/1981	23362	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	ITALY	17/08/1972	390577	17/08/1972	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	KAZAKSTAN	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	KOREA, NORTH	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals	York Pharma Plc	

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date
							B V	
FLAMMA ZINE	KYRGYZSTAN	22/11/1991	576642	25/12/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	LIBYA	28/01/2007	9935			Filing	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	F Y R MACEDONIA	17/08/1972	390577	23/07/1993	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	MADAGASCAR	05/09/1994	94/00157 D	27/10/1994	94/00036	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	MAURITIUS	08/01/1988		04/05/1988	A/28 NO 2 59	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	MOLDOVA	22/11/1991	576642	25/12/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	MONGOLIA	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	MOROCCO	11/12/1987		04/01/1988	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	MOROCCO	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	NETHERLANDS ANTILLES	07/03/1988	D-112	05/09/1988	14980	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	NICARAGUA	08/07/1993	93-01615	04/03/1994	25247C C	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	NIGERIA	30/04/2003	TP74863			Publication	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	O A P I / AFRICAN UNION **	06/05/1993	82403	15/07/1994	32754	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	PANAMA	03/08/1993	067207	13/06/1995	067207	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	PARAGUAY	16/04/1993	5639	16/12/1993	166808	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	PARAGUAY	02/10/2003	25270-2003	08/03/2007	296665	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	PERU	27/04/2004	4208816	04/10/2004	100343	Registration	Solvay Pharmaceuticals B V	York Pharma Plc
FLAMMA ZINE	PHILIPPINES	06/09/1973	SN24262	06/10/1975	22600	Registration	Solvay Pharmaceuticals	York Pharma Plc

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date	
							B V		
FLAMMA ZINE	POLAND	22/11/1991	576642	22/11/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	PORTUGAL	17/08/1972	390577	17/08/1972	390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	ROMANIA	17/08/1972	390577	16/09/1991	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	RUSSIAN FEDERATION	22/11/1991	576642	22/11/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	RUSSIAN FEDERATION	09/11/2005	2005728648	24/01/2007	319905	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SAN MARINO	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SERBIA	17/08/1972	390577	29/12/1975	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SLOVAKIA	17/08/1972	390577	01/01/1993	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SLOVENIA	17/08/1972	390577	01/12/1992	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SPAIN	17/08/1972	390577	17/08/1972	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SUDAN	17/08/1972	390577	13/02/1989	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SURINAME	15/08/2003	18818	15/08/2003	18818	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	SWITZERLAND	17/08/1972	390577	18/11/1974	R390577	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	TAJIKISTAN	22/11/1991	576642	25/12/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	UKRAINE	22/11/1991	576642	25/12/1991	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	UZBEKISTAN	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	
FLAMMA ZINE	VENEZUELA	18/05/1993	8737-93	10/07/1995	P178516	Registration	Solvay Pharmaceuticals B V	York Pharma Plc	Renewal is pending
FLAMMA ZINE	VIET NAM	18/11/1998	N983263	21/02/2000	33315	Registration	Solvay Pharmaceuticals	York Pharma Plc	

Trademark	Country	Filing date	Filing number	Registration date	Registration no	Current Status	Registered Owner	Planned Registered Owner Post Legal Transfer Date
							B V	
FLAMMA ZINE	VIET NAM	22/11/1991	576642	07/03/1994	579642	Registration	Solvay Pharmaceuticals B V	York Pharma Pic

*** French registration also covers:**

Overseas Departments

Guadeloupe
French Guyana
Martinique
Reunion

Overseas Territories

French Antarctic Territories
French Polynesia
New Caledonia
Wallis & Futuna

Territorial Communities

Mayotte
St -Pierre & Miquelon

**** OAPI = Organisation Africaine de la Propriété Intellectuelle.
Member states are:**

Benin
Burkina Faso
Cameroon
Central Africa
Congo (Brazzaville)
Ivory Coast
Gabon
Guinea
Guinea Bissau
Equatorial Guinea
Mali
Mauritania
Niger
Senegal
Tchad
Togo

General Information

Proposer including all trading names York Pharma plc and subsidiary companies*

Postal address

Burge End Farmhouse, Burge End Lane, Pirton, Nr Hitchin, Herts SG5 3QN

Telephone

Length of time based here

Email address

sue.keast@tesco.net

Website address

www.yorkpharma.co.uk

Business description

Marketing and supply of branded prescription products to pharmaceutical wholesalers, hospitals and general practitioners within the area of dermatology

Date business established

Company registration number

Trade association memberships

*York Pharma (UK) Limited, York Pharma GmbH, York Pharma (R&D), York Pharma KK, Rosanto Pharmaceuticals Limited, ACM Crawford SAS,

Crawford Healthcare Ltd and Dermo Development Ltd

Details

Schedule 6.01(v)
Insurance
Page 2 of 7

Description	Sum Insured / Limit of Indemnity	Notes
Commercial Combined - Policy Number PY-RKK692665		
<u>Property Damage</u>		
Burge End Farmhouse, Burge End Lane, Pilton, Nr Hitchin, Herts		RSA Group PLC, Leadenhall Court, 1 Leadenhall Street, London EC3V 1PP "All Risks" cover
General Contents	*£1,500	
Computer and Ancillary equipment	*£1,000	*15% day one uplift applies
Church House, Checkers Lane, Presson, Hitchin, Herts SG4 7TY		
General Contents	*£1,500	
Computer and Ancillary equipment	*£1,000	
The Innovation Centre, 217 Portabello, Sheffield S1 4DP		
General Contents	*£10,000	
Computer and Ancillary equipment	*£15,000	
Tenants Improvements	*£3,000	
Medical School, D Floor, Beech Hill Road, Sheffield S10 2RX		
General Contents	*£100,000	
Computer and Ancillary equipment	*£2,000	
Cheshire House, 164 Main Road, Goosetry, CW4 8JP		
Computer and Ancillary equipment	*£1,910	Crawford Interest of Rentsmart Limited noted
York House, Suite E1 and E2 Wilan Court, Upper 4th Street, Milton Keynes, MK90 1EH		
Computers and ancillary equipment	£10,600	
12 months rent	£45,220	

Schedule 6.01(v)
Insurance
Page 3 of 7

Description	Sum Insured / Limit of Indemnity	Notes
"All Risks" (anywhere in the world) 6 laptop computers	£6,000	
<u>Business Interruption</u> Innovation Centre Additional costs of working Book debts Medical School Additional costs of working Advanced Gross Profit	£24,000 £50,000 £320,000 £5,400,000	12 months Indemnity Period 12 months Indemnity Period 6 months Indemnity Period 3 months Indemnity Period 100% Suppliers Extension - CPM Contract Pharma
Gross Profit	£12,700,000	Applies in respect of Derris/Crawford activity Specified Perils apply 12 months Indemnity Period
Suppliers Extension		Perils of Fire, Lightning, Aircraft, Explosion only Full political and ideological terrorism extension Excluding fire following earthquake outside the UK
	£2,500,000	Dr August Wolf GmbH & Co, Germany
	£2,500,000	Ego, Pharmaceutical Pty Ltd, Australia
	£800,000	Laleham Healthcare Ltd, Hampshire, UK
	£500,000	Nycomed Pharma AS, Norway
	£1,500,000	Universal Products (Lytham), Lancs, UK
	£850,000	Custom Pharmaceuticals Ltd, East Sussex, UK
	£850,000	Laboratoire Carmain, France

**Schedule 6.01(v)
Insurance
Page 4 of 7**

Description	Sum Insured / Limit of Indemnity	Notes
Commercial Combined Contract Continued		
<u>Money Insurance</u> In transit/in premises In locked safes or strongrooms	£850,000 £1,000,000 £1,000,000	Laboratoire Crosmotec, Switzerland Chemotechnique Diagnostics, Sweden C P M Contactpharma GmbH & Co KG, Germany
<u>PA Assault Extension</u> Capital benefits T T D (per week) Medical Expenses	£4,000 £2,000 £10,000 £100 15%	Maximum 104 weeks of capital benefit
Description	Sum Insured/ Limit of Indemnity	Notes
Combined Liability - Policy Number 51435107A000/51436407A000		
<u>Employers Liability</u> Limit of Indemnity Wage roll	£10,000,000 £1,079,117	UK only
<u>Public/Products Liability</u> Limit of Liability Estimated Turnover	£5,000,000 £5,000,000	

**Schedule 6.01(v)
Insurance
Page 5 of 7**

Description	Sum Insured / Limit of Indemnity	Notes
Marine Transit - Policy Number GST050700450		
Storage at Sigma Aldrich Fine Chemicals	£75,000	Northern Marine Underwriters Limited, The Spirella Building, Bridge Road, Leitchworth, Herts SG6 4ET York Manufacture costs £75,000 (SAFC) Value of Penn's work £100,000 for above plus £68,000 for YP001 Crawford/Derms
Storage at Penn Pharmaceutical Services	£243,000	
Transit in UK	£25,000	
Transit of raw materials to manufacturers	£40,000	Note 1 Laleham Healthcare, GU34 2PR, UK Universal Products, PR4 3JA, UK Custom Pharmaceuticals, BN3 3LW, UK Ego Pharmaceuticals, Australia Laboratoire Car, France * Dr August Wolff, Germany Nycomed Pharma, Norway Laboratoire Crosmotec, Switzerland* *£80,000 flat over both locations
Storage of manufactured products at the manufacturers premises (see Note 1)	£300,000	
Transit to various logistics centres	£250,000	
Storage at logistics centres (see Note 2)	£1,000,000	
Specific limits will apply to individual premises -		Note 2 Movianto, UK Pharma Logistics, Belgium Blackhall Pharma, Eire Depots Generaux Pharma, France Homel Pharma, Germany
Specific limits apply -		
	£300,000	
	£1,000	
	£11,000	
	£250,000	
	£40,000	
	£82,000	
	£45,000	
	£40,000	
	£1,000,000	
	£8,250	
	£8,250	
	£3,500	
	£16,500	

**Schedule 6.01(v)
Insurance
Page 6 of 7**

Description	Sum Insured / Limit of Indemnity	Notes
Personal Accident/Travel - Policy Number 53UK603925		
<u>Personal Liability</u>		
Death	1 x salary	ACE European Group, ACE Building, 100 Leadenhall Street, London EC3A 3BP
PTD	3 x salary	
Injury	per scale	
<u>Travel</u>		
Medical Expenses	£5,500,000	All Directors and Employees 24 hour cover Aggregate aircraft limit £1,500,000 Aggregate per event £2,500,000 Maximum per person £722,000 All Directors and Employees
Personal Belongings	£10,000	
Money	£1,000	
Credit card misuse	£1,000	
Personal Liability	£2,000,000	
Overseas Legal Expenses	£50,000	
Directors and Officers Indemnity - Policy Number 82049202		
Limit of Liability	£3,000,000	Chubb Insurance Company of Europe S.A., Block B, Fifth Floor, Apex Plaza, Forbury Road, Reading, Berks RG1 1AX Excess nil other than claims in USA where excess \$35,000 applies

Title of condition/warranty	Brief purpose
<u>Commercial Combined</u> 15% day one uplift applies Excess £100 applies to claims arising from flood, escape of water from any tank, apparatus or pipe, malicious damage, theft or any attempted threat Electronic Risk Exclusion	
<u>Combined Liability</u>	
<u>Territorial Limits</u>	
1) Great Britain, Northern Ireland, the Isle of Man and the Channel Islands and Germany	
b) Elsewhere in the world	
<u>Jurisdiction</u>	
Worldwide excluding USA/Canada	
Excess £2,500 each and every claim including costs and expenses	
<u>Goods in Transit (Marine)</u>	
Standard Institute Clauses	
Excess £100 each claim but increased to £250 during storage	



CERTIFICATE OF THE REGISTRATION OF A MORTGAGE OR CHARGE

Pursuant to section 401(2) of the Companies Act 1985

**COMPANY NO. 3322659
CHARGE NO. 1**

THE REGISTRAR OF COMPANIES FOR ENGLAND AND WALES
HEREBY CERTIFIES THAT A SECURITY AGREEMENT DATED 30
SEPTEMBER 2008 AND CREATED BY ROSANTO
PHARMACEUTICALS LTD FOR SECURING ALL MONIES DUE
OR TO BECOME DUE FROM ANY LOAN PARTY TO ANY
SECURED PARTY, ANY AFFILIATE OF ANY SECURED PARTY,
OR ANY PERSON ON ANY ACCOUNT WHATSOEVER UNDER
THE TERMS OF THE AFOREMENTIONED INSTRUMENT
CREATING OR EVIDENCING THE CHARGE WAS REGISTERED
PURSUANT TO CHAPTER 1 PART XII OF THE COMPANIES ACT
1985 ON THE 16 OCTOBER 2008

GIVEN AT COMPANIES HOUSE, CARDIFF THE 17 OCTOBER
2008

Handwritten signature



Companies House
— for the record —



THE OFFICIAL SEAL OF THE
REGISTRAR OF COMPANIES